


NovartisOncology



EHA25 Virtual Congress

Highlights of Accepted Novartis Data



Myelodysplastic Syndrome (MDS) / Acute Myeloid Leukemia (AML)

MBG453

Abstract # S185 - Oral

June 14, 2020 | 8:00 am CEST

Anti-TIM-3 antibody MBG453 in combination with hypomethylating agents in patients with high-risk MDS and AML: a Phase 1 study

Chronic Myeloid Leukemia (CML)

Asciminib (ABL001)

Abstract # S170 - Oral

June 12, 2020 | 8:30 am CEST

Asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase sensitive to tyrosine kinase inhibitor (TKI) therapy

Graft-versus-Host Disease (GvHD) / Myeloproliferative Neoplasms (MPNs)

Jakavi® (ruxolitinib)

Abstract # S255 - Oral

June 12, 2020 | 8:00 am CEST

Ruxolitinib versus best available therapy in patients with steroid-refractory acute GvHD: overall response rate by baseline characteristics in the randomized Phase 3 REACH2 trial

Abstract # EP1112 - Poster

June 12, 2020 | 8:00 am CEST

Patient-reported physical, emotional and economic impact of MPNs in an expansion of the MPN Landmark Survey

Abstract # EP1123 - Poster

June 12, 2020 | 8:00 am CEST

Treatment and disease management practices in patients with MPNs in 6 countries: an expansion of the MPN Landmark Survey

Sickle Cell Disease (SCD)

Adakveo® (crizanlizumab)

Abstract #PB2362 - Publication Only

STEADFAST: A randomized, multicenter, open-label, Phase II study investigating the effect of crizanlizumab plus standard of Care (SoC) versus SoC alone on renal function in patients with chronic kidney disease due to sickle cell nephropathy

Abstract # EP1524 - Poster

June 12, 2020 | 8:00 am CEST

Use of opioids in patients with SCD: a country and age analysis of the International Sickle Cell World Assessment Survey (SWAY)

Abstract # EP1515 - Poster

June 12, 2020 | 8:00 am CEST

Incidence and management of vaso-occlusive crises in patients with SCD: a country and age analysis of SWAY

Abstract # EP1539 - Poster

June 12, 2020 | 8:00 am CEST

Patient and healthcare professional perceptions of SCD impact on daily life, symptom burden and treatment: results from SWAY

Idiopathic Thrombocytopenic Purpura (ITP)

Revolade® (eltrombopag)

Abstract # EP1642 - Poster

June 12, 2020 | 8:00 am CEST

Higher symptom burden in patients with ITP experiencing fatigue: results from the ITP World Impact Survey (I-WISH)

Abstract # EP1654 - Poster

June 12, 2020 | 8:00 am CEST

A patient's perspective on impact of ITP on emotional wellbeing: a patient's perspective from I-WISH

Abstract # EP1631 - Poster

June 12, 2020 | 8:00 am CEST

Patients' reported perceptions on satisfaction with ITP treatments: results from I-WISH

